Market-based licensing for HPV vaccines in developing countries.
Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.
Outterson
Kevin
K
Boston University School of Law, USA. mko@bu.edu
Kesselheim
Aaron S
AS
D003906:Developing Countries / Q000191:economics*; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D004465:Economic Competition; D005260:Female; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D008004:Licensure / Q000331:legislation & jurisprudence*; D053918:Papillomavirus Vaccines / Q000191:economics* / Q000600:supply & distribution; D011306:Prescription Fees / Q000331:legislation & jurisprudence*; D012109:Research Support as Topic
D053918:Papillomavirus Vaccines